Relay Therapeutics, Inc.
RLAY
Rank in Stocks
#4233
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Share Price
$17.16
Last synced: 2026-10-19
Market Cap
$3.76B
Change (1 day)
5.41%
Change (1 year)
140.34%
Country
US
Trade Relay Therapeutics, Inc. (RLAY)
Category
Healthcare
Number of shares outstanding for Relay Therapeutics, Inc. (RLAY)
Number of shares outstanding as of June 2026: 202.85M
According to Relay Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 202.85M. At the end of December 2023 the company had 122.58M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Relay Therapeutics, Inc. (RLAY) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 202.85M | 41.98% |
| 2024 | 142.87M | 16.55% |
| 2023 | 122.58M | 9.22% |
| 2022 | 112.23M | 17.97% |
| 2021 | 95.14M | 5.65% |
| 2020 | 90.05M | 2,003.45% |
| 2019 | 4.28M | 72.27% |
| 2018 | 2.49M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 25.17% |
US
|
|
| 396.00M | 95.22% |
US
|
|
| 478.91M | 136.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -69.34% |
NL
|
